durvalumab

1. 02:42
   x.com

   #ScienceLink #Madrid2026 #ESMO26 #DUOE #CancerDeEndometrio
2. 01:36
   x.com

   Interim OS data from the Phase 3 DUO-E/GOG-3041/ENGOT-EN10 study at #ESMO26 show CP + durvalumab, followed by durvalumab with or without olaparib, was favored compared with CP alon
3. 01:32
   x.com

   💡#ESMO26 I Durvalumab más enfortumab vedotin reduce un 42% el riesgo de muerte en cáncer de vejiga músculo-invasivo no candidato a cisplatino. @myesmo. https://www.diariomedico.com
4. 01:27
   x.com

   A new SoC in extensive disease small cell lung cancer: Durvalumab plus Tarlatamab. 79% patients alive at 1 year. #ESMO26 #LungCancer @myESMO @_SEOM @gecp_org
5. 01:19
   x.com

   In patients with muscle-invasive bladder cancer, event-free survival at 24 months was 63.5% with perioperative #durvalumab plus neoadjuvant enfortumab vedotin as compared with 45.1
6. 00:53
   x.com

   💡#ESMO26 I Durvalumab más enfortumab vedotin reduce un 42% el riesgo de muerte en cáncer de vejiga músculo-invasivo no candidato a cisplatino. @myesmo. https://www.diariomedico.com

1. 23:35
   x.com

   A new milestone for peri-op MIBC at #ESMO26 ! Durvalumab w/ or w/o tremelimumab in combination with EV (only adjuvant) improved survival outcomes!
2. 23:33
   x.com

   3 dose of EV plus Durvalumab should be new SOC for this set of pts . Less is more . @myESMO @OncoAlert #esmo26 @tompowles1
3. 23:20
   x.com

   #ESMO26, presentati in una sessione Proffered Paper del Presidential Symposium I i risultati di uno studio di Fase III sul #tumoredellavescica muscolo-invasivo: https://www.medinew
4. 23:20
   x.com

   Novità sul trattamento del #tumoredellavescica muscolo-invasivo da #ESMO26.
5. 21:07
   x.com

   Phase 3 DUO-E results show that adding durvalumab and olaparib to treatment extended median overall survival by 11.5 months for patients with advanced or recurrent endometrial canc
6. 19:23
   x.com

   #ESMO26 Can molecular profiling identify who benefits most from perioperative durvalumab in MIBC?
7. 18:02
   x.com

   #ESMO26 🇪🇸 | POP-DURVA Phase II
8. 17:27
   x.com

   NIAGARA biomarker analysis at #ESMO26
9. 16:07
   x.com

   POP-Durva | #ESMO26
10. 15:51
    x.com

    Great presentation about translational analysis in durvalumab response in TNBC by Joana Ribeiro at #ESMO2026
11. 15:44
    x.com

    ESMO 2026 | Does immune activation translate into tumor eradication?
12. 15:39
    x.com

    🔹In POP-Durva, analyses on paired biopsies show immmune activation after 2 administrations of durvalumab in stage 1 TNBC
13. 15:34
    x.com

    📌 Short-term preoperative durvalumab for stage I TNBC: First results from the phase II UNLOCK 14 - POP-DURVA trial
14. 15:32
    x.com

    Oral abstract #BreastCancer session at #ESMO26: use pre-operative #durvalumab without chemotherapy in patients with cT1 cN0 triple-negative disease
15. 15:32
    x.com

    POP-DURVA
16. 15:32
    x.com

    #ESMO26 | POP-DURVA – Phase II
17. 06:35
    x.com

    #ESMO26 | POP-DURVA

1. 02:42
   clinicaltrials.gov

   Zolbetuximab, Durvalumab, and FLOT Combination Neoadjuvant Chemotherapy for CLDN18.2-Positive Gastric Cancer or Gastroesophageal Junction Adenocarcinoma

Heat now 141·Peak in the comparable set 183 (Oct 25 03:00)·Change over 24h in the comparable set –·Participants now 22

Participants counted above, heat below. The trend compares only the participants observed in full throughout, so its set can be smaller than the heat figure itself. Move the pointer or click the chart for an hour's reading; the left and right arrow keys work too.